SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

Castro, Cristina Grávalos; Santasusana, Joan Maurel; Herrero, F. Rivera; Soler, Ramón Salazar; García, Isabel; Valera, Javier Sastre; Tabernero, Josep; Flores, Encarnación González; Garrido, M.; Isla, Dolores

doi:10.1007/s12094-010-0586-5

Cited by 14 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant chemotherapy for colon cancer was administered according to the norms of the American Society of Clinical Oncology (ASCO) and the Spanish Society of Medical Oncology (SEOM) (31,32). Locally advanced rectal cancers (at stages cT3-4 or cN1) and clinically bulky tumors received external radiotherapy (45 Gy to 54 Gy) neoadjuvant treatment over four weeks in combination with 5-fluorocil-based chemotherapy, according to a regimen described previously (33).…”

Section: Methodsmentioning

confidence: 99%

“…Locally advanced rectal cancers (at stages cT3-4 or cN1) and clinically bulky tumors received external radiotherapy (45 Gy to 54 Gy) neoadjuvant treatment over four weeks in combination with 5-fluorocil-based chemotherapy, according to a regimen described previously (33). All patients were monitored according to the guidelines established by the SEOM (32,34).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Colon cancer (CC) is the third most common cancer in both genders worldwide and the second cause of cancer-related death in western countries, only overcome by lung cancer [1, 2]. In Cuba, CC is one of the most frequent tumors and the third cause of death by cancer in both men and women [3].…”

Section: Introductionmentioning

confidence: 99%

“…Despite the significant advances in the treatment and knowledge of the colon tumor biology over the last decade, the 5-year survival after surgery varies from 90% to 10%, depending on stage and progression of disease [2, 4]. Therefore, it is important to increase our understanding of the molecular changes leading to development, spread, and metastasis and to identify potential prognostic and predictive markers for the disease.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer

Lahera

Calvo

Torres

et al. 2014

Journal of Oncology

View full text Add to dashboard Cite

Purpose. To assess the prognostic role of 14F7 Mab immunoreactivity, against N-Glycolyl GM3 ganglioside, in patients with colon cancer (CC) and to evaluate the relationship between its expression and clinicopathological features. Methods. Paraffin-embedded specimens were retrospectively collected from 50 patients with CC operated between 2004 and 2008. 14F7 Mab staining was determined by immunohistochemistry technique and its relation with survival and clinicopathologic features was evaluated. Results. The reactivity of 14F7 Mab was detected in all cases. Most cases had high level of immunostaining (70%) that showed statistical correlation with TNM stage (P = 0.025). In univariate survival analysis, level of 14F7 Mab immunoreactivity (P = 0.0078), TNM Stage (P = 0.0007) and lymphovascular invasion (0.027) were significant prognostic factors for overall survival. Among these variables, level of 14F7 Mab immunoreactivity (HR = 0.268; 95% CI 0.078–0.920; P = 0.036) and TNM stage (HR = 0.249; 95% CI 0.066–0.932; P = 0.039) were independent prognostic factors on multivariate analysis. Conclusions. This study is the first approach on the prognostic significance of 14F7 Mab immunoreactivity in patients with colon adenocarcinoma and this assessment might be used in the prognostic estimate of CC, although further studies will be required to validate these findings.

show abstract

“…Pathological typing of tumor tissues was performed to evaluate the infiltration degree based on the UICC standard [ 6 ]. The diagnosis of lymph node differentiation and metastasis was performed according to WHO guidelines [ 7 ]. Post-operative follow-up was performed on all patients once per month for a maximum duration of 5.5 years (average=3.6 years).…”

Section: Methodsmentioning

confidence: 99%

MicroRNA-421 Gene Polymorphism in Gastric Carcinoma

Jin

Nong

2016

Med Sci Monit

View full text Add to dashboard Cite

BackgroundAs a common malignant tumor, gastric carcinoma requires early diagnosis to improve treatment efficacy. MicroRNA (miR) molecules have highly conserved nucleotide sequences and can negatively regulate target gene expression at the translational level. miR-421 has been suggested to be related with gastric cancer occurrence. The gene polymorphism of miR-421, however, has not been reported. This study thus investigated the G/C polymorphism of miR-421 and its role in progression and prognosis of gastric cancer.Material/MethodsA total of 96 gastric cancer patients were recruited in this study and tumor samples were collected from surgical resection. Single-nucleotide polymorphism (SNP) of miR-421 was determined by DNA sequencing for analyzing the correlation between lymph node metastasis and miR-421 genotypes. Logistic regression analysis was used to determine the relationship between genotype and risk factors of gastric cancer. Kaplan-Meier survival analysis was also performed to compare GG and GC carriers.ResultsDifferential expression patterns existed between gastric cancer tissues and normal gastric mucosa. Logistic regression analysis showed GC and GG genotypes were risk factors for gastric cancer. Patients with lymph node metastasis had higher GG genotype frequency compared to those without metastasis. In survival analysis, GG carriers had shorter survival time than GC carriers. Furthermore, GG genotype was correlated with tumor prognosis (p<0.05).ConclusionsG allele of miR-421 is a risk factor for gastric cancer. GG genotype is correlated with lymph node metastasis and prognosis, indicating it is a risk factor for gastric cancer.

show abstract

SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

Cited by 14 publications

References 23 publications

Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers

Screening-detected colorectal cancers show better long-term survival compared with stage-matched symptomatic cancers

Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer

MicroRNA-421 Gene Polymorphism in Gastric Carcinoma

Contact Info

Product

Resources

About